Close Ham Menu
1200 Summit Avenue, Suite 414 Fort Worth, TX 76102
(817) 529-2300
Neep Help? Email us at customerservice@sanaramedtech.com
Search
Ham Menu

ALLOCYTE® Plus Advanced
Viable Bone Matrix

ALLOCYTE® Plus Advanced Viable Bone Matrix is a next-
generation cellular bone allograft with viable, bone-derived
progenitor cells and DMSO-free cryoprotectant.

Product Brochure IFU
ALLOCYTE® Plus Advanced Viable Bone Matrix

Distinguishing Features

  • Handling:

    Demineralized cortical bone fibers provide robust and conformable handling. Packaged in an open bore syringe to allow delivery directly from the syringe.

  • Non-cytotoxic:

    Cryopreserved using a DMSO-free cryoprotectant, eliminating the need to rinse and decant the tissue prior to implantation.

  • Viable Cell Population:

    1.5 million viable cells per cc of allograft ideal for osteogenic supplementation.
Distinguishing Features

Graft viability post thaw

4 Hours

Thaw in warm saline without decanting for

10 Minutes

Cell viability post-thaw is at least

92%

of initial viable and active cell count

allocyte

Cells protected by proprietary cryoprotectant

  • Protective coating preserves allograft and prevents crack propogation and membrane lysis
  • Non-cytotoxic, non-DMSO
ALLOCYTE® Plus Advanced Viable Bone Matrix Proprietary DMSO-free cryoprotectant
ALLOCYTE® Plus Advanced
Viable Bone Matrix Proprietary
DMSO-free cryoprotectant
2.5% DMSO solution
2.5% DMSO solution

Cytotoxicity assay showing higher number of viable cells in media containing up to 10% cryoprotectant (left) compared to media containing 2.5% DMSO (right), after 48 hours incubation period.

References

  • 1. Data on file.
  • 2. Data on file
Doctor

Keep Up With the Latest Developments
in Surgical and Wound Care Technology

Sign Up for the Sanara MedTech Mailing List

Most Recent Press Releases

Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)

March 25, 2025

Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

March 12, 2025

Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd

January 22, 2025
All Press Releases
Contact Sanara MedTech

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Logo

© 2025 All Rights Reserved. Sanara MedTech Inc.

Privacy Policy Terms of Use